Systemic lupus erythematosus, lupus nephritis and end-stage renal disease: a pragmatic review mapping disease severity and progression

被引:121
作者
Mahajan, Anadi [1 ]
Amelio, Justyna [2 ]
Gairy, Kerry [3 ]
Kaur, Gavneet [1 ]
Levy, Roger A. [4 ]
Roth, David [4 ]
Bass, Damon [4 ]
机构
[1] Bridge Med, Richmond, Surrey, England
[2] GlaxoSmithKline, Real World Evidence & Epidemiol, Stevenage, Herts, England
[3] GlaxoSmithKline, Value Evidence & Outcomes, Brentford, England
[4] GlaxoSmithKline, Collegeville, PA USA
关键词
Nephritis; renal lupus; systemic lupus erythematosus; PROGNOSIS; OUTCOMES; CLASSIFICATION; BIOPSY; COHORT; DIAGNOSIS; UPDATE; RISK;
D O I
10.1177/0961203320932219
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective The understanding of systemic lupus erythematosus (SLE) and lupus nephritis (LN) pathogenesis remains incomplete. This review assessed LN development in SLE, within-LN progression and progression to end-stage renal disease (ESRD). Methods A keyword-based literature search was conducted, and 26 publications were included. Results Overall, 7-31% of patients had LN at SLE diagnosis; 31-48% developed LN after SLE diagnosis, most within 5 years. Class IV was the most commonly found LN class and had the worst prognosis. Histological transformation occurred in 40-76% of patients, more frequently from non-proliferative rather than proliferative lesions. Cumulative 5- and 10-year ESRD incidences in patients with SLE were 3% and 4%, respectively, and 3-11% and 6-19%, respectively, in patients with SLE and LN. Conclusions Elevated serum creatinine was identified as a predictor of worsening disease state, and progression within LN classes and from SLE/LN to ESRD. This review highlights the substantial risk for developing LN and progressing to ESRD amongst patients with SLE.
引用
收藏
页码:1011 / 1020
页数:10
相关论文
共 50 条
[1]   An assessment of renal failure in an SLE cohort with special reference to ethnicity, over a 25-year period [J].
Adler, M. ;
Chambers, S. ;
Edwards, C. ;
Neild, G. ;
Isenberg, D. .
RHEUMATOLOGY, 2006, 45 (09) :1144-1147
[2]   Lupus nephritis among 624 cases of systemic lupus erythematosus in Riyadh, Saudi Arabia [J].
Al Arfaj, Abdurahman Saud ;
Khalil, Najma ;
Al Saleh, Salman .
RHEUMATOLOGY INTERNATIONAL, 2009, 29 (09) :1057-1067
[3]   Update on Lupus Nephritis [J].
Almaani, Salem ;
Meara, Alexa ;
Rovin, Brad H. .
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (05) :825-835
[4]   Contemporary treatment of systemic lupus erythematosus: an update for clinicians [J].
Amissah-Arthur, Maame B. ;
Gordon, Caroline .
THERAPEUTIC ADVANCES IN CHRONIC DISEASE, 2010, 1 (04) :163-175
[5]   Prognosis in proliferative lupus nephritis: the role of socio-economic status and race/ethnicity [J].
Barr, RG ;
Seliger, S ;
Appel, GB ;
Zuniga, R ;
D'Agati, V ;
Salmon, J ;
Radhakrishnan, J .
NEPHROLOGY DIALYSIS TRANSPLANTATION, 2003, 18 (10) :2039-2046
[6]   Rituximab in Systemic Lupus Erythematosus and Lupus Nephritis [J].
Beckwith, Hannah ;
Lightstone, Liz .
NEPHRON CLINICAL PRACTICE, 2014, 128 (3-4) :250-254
[7]   EULAR recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR standing committee for international clinical studies including therapeutics [J].
Bertsias, G. ;
Ioannidis, J. P. A. ;
Boletis, J. ;
Bombardieri, S. ;
Cervera, R. ;
Dostal, C. ;
Font, J. ;
Gilboe, I. M. ;
Houssiau, F. ;
Huizinga, T. ;
Isenberg, D. ;
Kallenberg, C. G. M. ;
Khamashta, M. ;
Piette, J. C. ;
Schneider, M. ;
Smolen, J. ;
Sturfelt, G. ;
Tincani, A. ;
van Vollenhoven, R. ;
Gordon, C. ;
Boumpas, D. T. .
ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (02) :195-205
[8]  
Cojocaru Manole, 2011, Maedica (Bucur), V6, P330
[9]   Assessment of a lupus nephritis cohort over a 30-year period [J].
Croca, Sara C. ;
Rodrigues, Teresa ;
Isenberg, David A. .
RHEUMATOLOGY, 2011, 50 (08) :1424-1430
[10]   What is damaging the kidney in lupus nephritis? [J].
Davidson, Anne .
NATURE REVIEWS RHEUMATOLOGY, 2016, 12 (03) :143-153